Clinical trial
Effect of Sulodexide in Overt Diabetic Nephropathy
NCT00130312 · Keryx Biopharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00130312 |
|---|---|
| Title | Effect of Sulodexide in Overt Diabetic Nephropathy |
| Official title | The Collaborative Study Group Trial: The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy |
| Lead sponsor | Keryx Biopharmaceuticals, Industry |
| Collaborators | Collaborative Study Group (CSG) |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetic Nephropathy |
| Intervention type | Drug |
| Interventions | Sulodexide, Placebo |
| Enrollment | 968 |
| Start date | Aug 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Aug 15, 2005 |
| Last update posted | Mar 19, 2021 |
| Countries | Australia, Netherlands, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: